[Serum type III procollagen in dilated cardiomyopathy]

Area of Science:

• Cardiology
• Biochemistry
• Medical Diagnostics

Background:

• Dilated cardiomyopathy (DCMP) is a serious cardiac condition.
• Myocardial fibrosis and inflammation are key pathological features of DCMP.
• Accurate diagnostic markers for these conditions are crucial.

Purpose of the Study:

• To investigate serum procollagen type III end protein (PEP) levels in patients with DCMP.
• To compare PEP levels between DCMP, coronary heart disease (CHD) patients, and healthy donors.
• To assess the diagnostic potential of PEP for myocardial inflammation and fibrosis.

Main Methods:

• Radioimmunoassay (RIA) was used to measure serum PEP concentrations.
• Study included 11 DCMP patients, 9 CHD patients, and healthy donors.
• Statistical analysis was performed to determine significance of differences.

Main Results:

• Mean serum PEP levels were significantly higher in DCMP patients (8.8 ± 7.9 µg/l) compared to CHD patients (4.4 ± 1.6 µg/l) and donors (1.7 ± 1.4 µg/l) (p < 0.05).
• Over 54% of DCMP patients exhibited PEP levels exceeding 4.5 µg/l.
• Highest PEP concentrations were observed in severe DCMP cases (NYHA class IIB-III, pulmonary thromboembolism).

Conclusions:

• Serum PEP is a significant biomarker differentiating DCMP from CHD and healthy states.
• Elevated PEP levels correlate with myocardial inflammation and fibrosis.
• PEP determination shows promise for laboratory diagnosis of myocardial damage in DCMP.